Floatz logo

XENON

Pulmonary Fibrosis

Duke UniversitySmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Acetylcysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Sildenafil
Alicia Gerke
Phase 3BB

View all 34 →

Same molecule, other indications

XENON is also rated in:

cystic fibrosisActive
BB
Indicative · Phase 4
65 / 100
View asset →
asthmaActive
B
Indicative · Phase 2
63 / 100
View asset →
idiopathic pulmonary fibrosisActive
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →